Table 3.
Overall |
0 Chronic conditions |
1–2 Chronic conditions |
3+ Chronic conditions |
Overall |
0 Chronic conditions |
1–2 Chronic conditions |
3+ Chronic conditions |
|
---|---|---|---|---|---|---|---|---|
0.4 mg/g | 2.4 mg/g | |||||||
Satisfaction | 3.23 ± 0.15a | 3.47 ± 0.21 | 2.63 ± 0.20 | 3.61 ± 0.34 | 3.54 ± 0.15be | 3.64 ± 0.21 | 3.55 ± 0.20 | 3.45 ± 0.34 |
Psychological reward | 2.69 ± 0.14a | 2.84 ± 0.19 | 2.18 ± 0.18 | 3.05 ± 0.30 | 2.75 ± 0.14ab | 2.86 ± 0.19 | 2.66 ± 0.18 | 2.72 ± 0.30 |
Aversion | 1.48 ± 0.15a | 1.47 ± 0.16 | 1.53 ± 0.18 | 1.45 ± 0.23 | 1.52 ± 0.15a | 1.55 ± 0.16 | 1.53 ± 0.18 | 1.48 ± 0.23 |
Enjoyment of Respiratory tract sensations | 2.85 ± 0.16a | 3.29 ± 0.22 | 2.41 ± 0.21 | 2.85 ± 0.37 | 2.99 ± 0.16b | 3.39 ± 0.22 | 2.98 ± 0.21 | 2.61 ± 0.36 |
Craving reduction | 3.33 ± 0.29a | 3.47 ± 0.33 | 2.85 ± 0.34 | 3.67 ± 0.46 | 3.52 ± 0.29ab | 3.54 ± 0.33 | 3.55 ± 0.34 | 3.47 ± 0.46 |
Overall |
0 Chronic conditions |
1–2 Chronic conditions |
3+ Chronic conditions |
Overall |
0 Chronic conditions |
1–2 Chronic conditions |
3+ Chronic conditions |
|
---|---|---|---|---|---|---|---|---|
5.2 mg/g | 15.8 mg/g | |||||||
Satisfaction | 3.81 ± 0.15ce | 4.07 ± 0.21 | 3.59 ± 0.20 | 3.76 ± 0.34 | 4.55 ± 0.15 d | 4.83 ± 0.21 | 4.41 ± 0.20 | 4.43 ± 0.34 |
Psychological reward | 3.02 ± 0.14b | 3.11 ± 0.19 | 2.77 ± 0.18 | 3.19 ± 0.30 | 3.44 ± 0.14c | 3.47 ± 0.19 | 3.09 ± 0.18 | 3.77 ± 0.30 |
Aversion | 1.51 ± 0.15a | 1.46 ± 0.16 | 1.62 ± 0.18 | 1.44 ± 0.23 | 1.75 ± 0.15b | 1.77 ± 0.16 | 1.81 ± 0.18 | 1.66 ± 0.23 |
Enjoyment of respiratory tract sensations | 3.49 ± 0.16c | 3.79 ± 0.22 | 3.23 ± 0.21 | 3.47 ± 0.37 | 4.07 ± 0.16d | 4.28 ± 0.22 | 3.90 ± 0.21 | 4.04 ± 0.37 |
Craving reduction | 3.81 ± 0.29b | 3.92 ± 0.33 | 3.73 ± 0.34 | 3.79 ± 0.46 | 4.41 ± 0.29c | 4.41 ± 0.33 | 4.38 ± 0.34 | 4.43 ± 0.46 |
Note. Tabled values represent least square means ± SEM. Overall ratings collapsed across all subjects and by CCS are displayed by dose. Post-hoc testing is shown on subscales within the overall group where there were main effects of dose; data points not sharing a superscript letter differed significantly after Bonferroni correction. There were no significant differences by CCS, so no post hoc testing between CCS groups were conducted.